Home
|
Inbox
|
Search
|
View Abstract
Applying Epix™ Technology to Enable Ex Vivo Theratyping Using Airway Epithelial Cells Derived from Patients with Pulmonary Diseases
Description
.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px } .abstract { overflow-x:scroll } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px } .abstract td, th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; } .abstract a { overflow-wrap: break-word; word-wrap: break-word; }
A7742 - Applying Epix™ Technology to Enable Ex Vivo Theratyping Using Airway Epithelial Cells Derived from Patients with Pulmonary Diseases
Author Block: C. Zhang1, A. Shrivastava1, H. Bihler2, J. Harrington2, I. Musisi2, M. Mense2, S. H. Randell3, M. J. Bruehl4, M. S. Muhlebach5, T. J. McQuiston1, S. S. Challberg1, B. A. Pollok1; 1Propagenix Inc., Rockville, MD, United States, 2Cystic Fibrosis Foundation, Lexington, MA, United States, 3Cell Biology and Physiology/Marsico Lung Institute, University of North Carolina, Chapel Hill, NC, United States, 4Department of Pediatrics, University of North Carolina, Chapel Hill, NC, United States, 5University of North Carolina, Chapel Hill, NC, United States.
We have developed a patented feeder-free and serum-free cell culture technology (EpiX™), which utilizes small molecules inhibiting TGF-β signaling pathway together with cytoskeleton dynamics modulation, to achieve more than one trillion-fold propagation of basal epithelial stem cells from skin, airway, mammary, prostate and other epithelia in standard 2D cell culture.
Notable attributes of the EpiX™ technology include:
1. Patented serum-free and feeder-free formulations allow more than one trillion-fold expansion of primary human airway epithelial cell in vitro, while preserving genomic integrity
2. Airway epithelial cells expanded using EpiX™ technology retain their lineage-committed differentiation capacity, and can seamlessly integrate into standard airway differentiation protocols
3. EpiX™-expanded airway epithelial cells retain consistent CFTR and ENaC activities even after extensive propagation for at least 8 passages, allowing the generation of millions of cell-models for airway epithelial function evaluation
4. EpiX™ enables the derivation of hundreds of millions of airway epithelial cells in a short time from small number of primary cells such as nasal brushing samples in 3-4 weeks
5. Extended proliferation runway empowers genetic engineering to develop high-throughput screening models
6. 2nd generation chemically-defined animal-origin-free formulations satisfy upcoming regulatory guidance
Applying EpiX™ medium can enable extensive expansion of human airway epithelial cells from patients with pulmonary diseases for in vitro theratyping to identify which drug(s) could benefit individual patients. Combined with genome editing technology, EpiX™ technology also enables us to address attaining sufficient basal epithelial stem cells for cell therapy and regenerative medicine applications.
Author Block: C. Zhang1, A. Shrivastava1, H. Bihler2, J. Harrington2, I. Musisi2, M. Mense2, S. H. Randell3, M. J. Bruehl4, M. S. Muhlebach5, T. J. McQuiston1, S. S. Challberg1, B. A. Pollok1; 1Propagenix Inc., Rockville, MD, United States, 2Cystic Fibrosis Foundation, Lexington, MA, United States, 3Cell Biology and Physiology/Marsico Lung Institute, University of North Carolina, Chapel Hill, NC, United States, 4Department of Pediatrics, University of North Carolina, Chapel Hill, NC, United States, 5University of North Carolina, Chapel Hill, NC, United States.
We have developed a patented feeder-free and serum-free cell culture technology (EpiX™), which utilizes small molecules inhibiting TGF-β signaling pathway together with cytoskeleton dynamics modulation, to achieve more than one trillion-fold propagation of basal epithelial stem cells from skin, airway, mammary, prostate and other epithelia in standard 2D cell culture.
Notable attributes of the EpiX™ technology include:
1. Patented serum-free and feeder-free formulations allow more than one trillion-fold expansion of primary human airway epithelial cell in vitro, while preserving genomic integrity
2. Airway epithelial cells expanded using EpiX™ technology retain their lineage-committed differentiation capacity, and can seamlessly integrate into standard airway differentiation protocols
3. EpiX™-expanded airway epithelial cells retain consistent CFTR and ENaC activities even after extensive propagation for at least 8 passages, allowing the generation of millions of cell-models for airway epithelial function evaluation
4. EpiX™ enables the derivation of hundreds of millions of airway epithelial cells in a short time from small number of primary cells such as nasal brushing samples in 3-4 weeks
5. Extended proliferation runway empowers genetic engineering to develop high-throughput screening models
6. 2nd generation chemically-defined animal-origin-free formulations satisfy upcoming regulatory guidance
Applying EpiX™ medium can enable extensive expansion of human airway epithelial cells from patients with pulmonary diseases for in vitro theratyping to identify which drug(s) could benefit individual patients. Combined with genome editing technology, EpiX™ technology also enables us to address attaining sufficient basal epithelial stem cells for cell therapy and regenerative medicine applications.
|
Home
|
Inbox
|
Search
|